Status:
UNKNOWN
Efficacy of Hepatitis B Vaccine Boosters Among Neonatally Vaccinated Children in Chongqing
Lead Sponsor:
Children's Hospital of Chongqing Medical University
Conditions:
Hepatitis B Vaccine Adverse Reaction
Eligibility:
All Genders
1-15 years
Brief Summary
Worldwide, hepatitis B virus (HBV) infection is a major cause of acute hepatitis, and chronic infection with HBV often leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. So far...
Detailed Description
Hepatitis B virus (HBV) infection is a major public health problem around the world. More than 2 billion people have been infected with HBV. Although the World Health Organization (WHO) has incorporat...
Eligibility Criteria
Inclusion
- Born after Jan. 1st, 2005 in Chongqing, China;
- Completion of the full primary immunization of HepB after birth;
- No HBV booster vaccine history.
Exclusion
Key Trial Info
Start Date :
July 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03867643
Start Date
July 9 2021
End Date
December 31 2025
Last Update
March 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400014